{"@id":"https://bioecon.ru/technology/direct-acting-antivirals-hcv/","@type":"Technology","cluster":"therapeutics-platforms","formats":{"html":"https://bioecon.ru/technology/direct-acting-antivirals-hcv/","json":"https://bioecon.ru/api/v1/technology/direct-acting-antivirals-hcv/index.json"},"id":"direct-acting-antivirals-hcv","industries":["pharma","services","biomanufacturing"],"lang":"ru","links":{"industries":["https://bioecon.ru/industries/pharma/","https://bioecon.ru/industries/services/","https://bioecon.ru/industries/biomanufacturing/"],"suppliers":["https://bioecon.ru/companies/agc-biologics/","https://bioecon.ru/companies/btg-bioliquids/","https://bioecon.ru/companies/senseup-gmbh/","https://bioecon.ru/companies/veritree/","https://bioecon.ru/companies/pan-oleo-energy/","https://bioecon.ru/companies/groupe-roullier/","https://bioecon.ru/companies/resonac/"]},"maturity":9,"name":"Противовирусные препараты прямого действия при гепатите С (пангенотипные ингибиторы NS5B и NS5A)","regions":["us","cn","eu"],"risk":"low","section":"technology","sector":"health-biomedicine","sources":[{"date":"2026-11-15","entity":"who.int","kind":"official","urls":["https://www.who.int/publications/i/item/9789240052734"]},{"date":"2026-11-15","entity":"sciencedirect.com","kind":"research","urls":["https://doi.org/10.1016/j.jhep.2020.08.018"]}],"stages":[{"n":1,"title":null},{"n":2,"title":null},{"n":3,"title":null},{"n":4,"title":null},{"n":5,"title":null}],"summary":"Пероральные пангенотипные комбинации противовирусных препаратов прямого действия (софосбувир, велпатасвир, глекапревир), блокирующие ферменты NS5B и NS5A вируса гепатита С с эффективностью излечения \u003e95% за 8–12 недель.","url":"/technology/direct-acting-antivirals-hcv/","verified":"2026-11-15"}